|
|
Phase III Randomized Study of Selenium in Patients With Adenomatous Colorectal Polyps
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Related Information Registry Information
Alternate Title
Selenium in Treating Patients With Adenomatous Colorectal Polyps
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Prevention
|
|
|
|
Active
|
|
|
|
40 to 80
|
|
|
|
NCI
|
|
|
|
UARIZ-00-0430-01 00-0430-01, UARIZ-HSC-00142, NCT00078897
|
|
|
Special Category:
NCI Web site featured trial Objectives Primary - Compare the effects of selenium vs placebo on the recurrence of adenomatous colorectal polyps, in terms of histologic type, degree of dysplasia, number, size, and location, in patients with adenomatous colorectal polyps.
- Compare the type, incidence, and outcome of side effects in patients treated with these regimens.
- Determine patient adherence to long-term treatment with these regimens.
Secondary - Determine the effects of regimen modification by baseline blood selenium level, low-dose aspirin, selenoprotein genetic marker polymorphisms (e.g., GPx-1, GPx-2, and SEP15)
- Determine the effects of low-dose aspirin (81 mg/day) modification by ornithine decarboxylase promoter genotype, and toxicity by slow-metabolizer genotypes of the cytochrome p450 2C9 and UT1A6 loci in these patients.
Entry Criteria Disease Characteristics:
- Histologically confirmed colorectal adenomatous polyps
- Meets the following criteria by colonoscopy (performed within the past 6 months):
- Cecum was totally visualized or reached
- At least 90% visualization of colon surface area
- Removed at least 1 adenomatous polyp of at least 3 mm in size during procedure
- Removed no more than 10 adenomatous polyps of any size by endoscopy
- All other neoplastic and non-neoplastic colon polyps must have been completely removed (except for diminutive [less than 3 mm] sessile rectal polyps)
- For the sub-study, at least 1 advanced adenomatous polyp defined as 10 mm or greater in size and/or has villous histology and/or shows high grade dysplasia
- No prior diagnosis of any of the following:
- Colorectal cancer
- Familial adenomatous polyposis
- Ulcerative colitis
- Crohn's disease
- Hereditary non-polyposis colon cancer (HNPCC), defined as:
- Histologically confirmed colorectal cancer in at least 3 relatives, 1 of whom is a first-degree relative of the other 2
- Disease occurrence in at least 2 consecutive generations
- Colorectal cancer diagnosis in at least 1 family member who is less than 50 years of age
- Patients with a family history of colorectal cancer but who are not diagnosed with HNPCC are allowed
- No more than 1 prior segmental colon resection
Prior/Concurrent Therapy:
Biologic therapy - No concurrent drugs that regulate the immune system
Chemotherapy - No concurrent chemotherapy
Endocrine therapy Radiotherapy - No concurrent radiotherapy
Surgery - See Disease Characteristics
Other - Prior enrollment in another adenoma prevention study allowed
- Concurrent routine aspirin (≤ 81 mg/day) allowed
- No regular use of non-steroidal anti-inflammatory drugs (NSAIDs)
- No concurrent enrollment in another research study using pharmacological cancer drugs, a cyclo-oxygenase-2 inhibitor, or selenium
- No other concurrent selenium unless dosage is ≤ 50 µg/day
Patient Characteristics:
Age Performance status Life expectancy Hematopoietic - Hemoglobin > 11 g/dL
- WBC 3,000 - 11,000/mm3
Hepatic - AST and ALT < 2 times upper limit of normal
- Bilirubin < 2.0 mg/dL
Renal Cardiovascular - No unstable* cardiac disease despite medication (e.g., diuretics or digitalis)
- No uncontrolled hypertension (i.e., systolic blood pressure ≥ 170 mm Hg and/or diastolic blood pressure ≥ 110 mm Hg) despite medication
[Note: *Unstable defined as unable to walk across the room without chest pain or shortness of breath] Other - Not pregnant or nursing
- Fertile patients must use effective contraception for at least 2 months before and during study treatment
- Resident of a clinical center metropolitan area or obtaining regular health care in a clinical metropolitan area for at least 6 months out of the year
- Must be able to swallow pills
- No unexpected weight loss of 10% or more within the past 6 months
- No prior rheumatoid arthritis
- No poorly controlled diabetes mellitus despite medication, defined as:
- Blood sugar level ≥ 200 mg/dL on more than half of the readings taken within the past month
- No invasive malignancy within the past 5 years that required medical excision, radiotherapy, or chemotherapy except basal cell or squamous cell carcinoma
Expected Enrollment 2050A total of 1,850 patients will be accrued for this study followed by a second accrual of 200 patients with advanced adenoma for a substudy. Outcomes Primary Outcome(s)Recurrence rate and size of colorectal polyps reduction as measured by colonoscopy after 3-5 year of study treatment
Secondary Outcome(s)Tolerance and adequate adherence to long term selenium treatment as measured by adverse events, serious adverse events, every 3-4 months during treatment, and laboratory values at the beginning of the study , 6 months and annually thereafter
Outline This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to use of low-dose (≤ 81 mg/day) aspirin (yes vs no). Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive oral selenium once daily.
- Arm II: Patients receive oral placebo once daily.
In both arms, treatment continues for up to 5 years* in the absence of disease progression or unacceptable toxicity. Patients undergo follow-up colonoscopy approximately 5 years* after baseline colonoscopy. [Note: Some patients will continue participation for up to 7 and a half years]
Trial Contact Information
Trial Lead Organizations Arizona Cancer Center at University of Arizona Health Sciences Center | | | M. Peter Lance, MD, Principal investigator | | | | Trial Sites
|
|
|
|
U.S.A. |
|
Arizona |
|
|
Phoenix |
|
| | | | | | | | Veterans Affairs Medical Center - Phoenix |
| | Francisco Ramirez, MD | Ph: | 602-264-4461 | | 800-554-7174 |
|
|
|
Scottsdale |
|
| | Mayo Clinic Scottsdale |
| | Clinical Trials Office - All Mayo Clinic Locations | |
| | Virginia G. Piper Cancer Center at Scottsdale Healthcare - Shea |
| | Liane Fales, RN | |
| Email:
lfales@email.arizona.edu |
|
|
Tucson |
|
| | Arizona Cancer Center at University of Arizona Health Sciences Center |
| | Clinical Trials Office - Arizona Cancer Center at University of Arizona Health Sciences Center | |
|
Colorado |
|
|
Aurora |
|
| | | University of Colorado Cancer Center at UC Health Sciences Center |
| | Dennis Ahnen, MD | |
|
Texas |
|
|
Dallas |
|
| | | Baylor University Medical Center - Dallas |
| | Clinical Trials Office - Baylor University Medical Center - Dallas | |
|
Related Information Featured trial article
Registry Information | | Official Title | | Phase III Study of the Effects of Selenium on Adenomatous Polyp Recurrence | | Trial Start Date | | 2001-01-15 | | Trial Completion Date | | 2013-03-01 (estimated) | | Registered in ClinicalTrials.gov | | NCT00078897 | | Date Submitted to PDQ | | 2004-01-14 | | Information Last Verified | | 2008-11-06 | | NCI Grant/Contract Number | | CA23074, CA41108 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|